CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency

12-Apr-2022 - CureVac N.V. and GSK announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants the German federal government ...

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate

01-Apr-2022 - CureVac N.V. announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s ...

GSK and CureVac to develop next generation mRNA COVID-19 vaccines

Development to begin immediately targeting vaccine availability in 2022

03-Feb-2021 - GlaxoSmithKline plc and CureVac N.V. announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine.GSK will also ...

GSK and CureVac announce strategic mRNA technology collaboration

Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases

21-Jul-2020 - GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements ...

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Companies have set up a Joint Task Force

15-Apr-2020 - Sanofi and GSK announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA ...

GlaxoSmithKline plc and Pfizer Inc to form new Consumer Healthcare Joint Venture

20-Dec-2018 - GlaxoSmithKline plc has reached agreement with Pfizer Inc to combine their consumer health businesses into a new Joint Venture, with combined sales of approximately £9.8 billion ($12.7 billion). GSK will have a majority controlling equity interest of 68% and Pfizer will have an equity interest of ...

GSK transfers rare disease gene therapy portfolio

13-Apr-2018 - GSK and Orchard Therapeutics announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard’s ...

Novartis to sell stake in consumer healthcare joint venture to GSK

Focussing on strategic priorities

27-Mar-2018 - Novartis announced that it has entered into an agreement with GlaxoSmithKline plc (GSK) to divest its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for USD13.0 billion. The sale will enable Novartis to further focus on the development and growth of its core ...

GSK invests in genomic research in UK

07-Dec-2017 - GSK today welcomes the launch of the UK Government’s Life Sciences Sector Deal, which builds on the Industrial Strategy published by Sir John Bell earlier in the year, by announcing £40million of new money to strengthen initiatives that harness advances in genetic research in the development of ...

Plasticell and GSK sign collaboration agreement

Contains production of hematopoietic cells from iPSCs

18-Oct-2017 - Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) ...